Spinraza Evrópusambandið - íslenska - EMA (European Medicines Agency)

spinraza

biogen netherlands b.v. - nusinersen natríum - vöðvaáfall, mænu - Önnur lyf í taugakerfinu - spinraza er ætlað til meðferðar á 5q spítala.

Sinemet 12,5/50 Tafla 12,5 mg/50 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sinemet 12,5/50 tafla 12,5 mg/50 mg

n.v. organon* - carbidopum inn; levodopum inn - tafla - 12,5 mg/50 mg

Sinemet 25/100 Tafla 25 mg/100 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sinemet 25/100 tafla 25 mg/100 mg

n.v. organon* - levodopum inn; carbidopum inn - tafla - 25 mg/100 mg

Taptiqom sine (Taptiqom) Augndropar, lausn 15 microg/ml + 5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

taptiqom sine (taptiqom) augndropar, lausn 15 microg/ml + 5 mg/ml

santen oy* - tafluprostum inn; timololum maleat - augndropar, lausn - 15 microg/ml + 5 mg/ml

Cosopt sine Augndropar, lausn 20 mg/ml+5 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

cosopt sine augndropar, lausn 20 mg/ml+5 mg/ml

santen oy* - dorzolamidum hýdróklóríð; timololum maleat - augndropar, lausn - 20 mg/ml+5 mg/ml

LysaKare Evrópusambandið - íslenska - EMA (European Medicines Agency)

lysakare

advanced accelerator applications - l-arginine hydrochloride, l-lysine hydrochloride - geislun - detoxifying agents for antineoplastic treatment - lysakare er ætlað til að draga úr skert geislun á meina-viðtaka geislavirkni meðferð (prrt) með lutetium (177lu) oxodotreotide í fullorðnir.

Comirnaty Evrópusambandið - íslenska - EMA (European Medicines Agency)

comirnaty

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - bóluefni - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.